|
The National Academy of Clinical Biochemistry
Laboratory Medicine Practice Guidelines
Use of Tumor Markers in Liver, Bladder, Cervical, and Gastric Cancers
Published Guidelines
Access to Table of Contents
We present here to clinical chemists, clinicians and other practitioners of laboratory and clinical medicine the latest update of the national Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for the use of tumor markers in liver, bladder, cervical, lung and gastric cancers. These guidelines are intended to encourage more appropriate use of tumor marker tests by primary care physicians, hospital physicians and surgeons, specialist oncologists, and other health professionals.
Committee (Author) Disclosures
NACB Committee Members: |
Catharine M. Sturgeon
Department of Clinical Biochemistry, Royal Infirmary of Edinburgh, Edinburgh, UK
Michael J. Duffy
Department of Pathology and Laboratory Medicine, St Vincent’s University Hospital and UCD School of Medicine and Medical Science, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland
Barry R. Hoffman
Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, and Department of Laboratory Medicine and Pathobiology, University of Toronto, Ontario, Canada
Rolf Lamerz
Department of Medicine, Klinikum of the University Munich, Grosshadern, Germany
Herbert A. Fritsche
Department of Laboratory Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX
Katja Gaarenstroom
Department of Gynecology, Leiden University Medical Center, Leiden, the Netherlands
Johannes M.G Bonfrer
Department of Clinical Chemistry, Netherlands Cancer Institute, Amsterdam, the Netherlands
Thorsten Ecke
Department of Urology, Helios Hospital, Bad Saarow, Germany
H. Barton Grossman
Department of Urology, The University of Texas M. D. Anderson Cancer Center, Houston, TX
Peter Hayes
Scottish Liver Transplant Unit, Department of Medicine, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom
Ralf-Thorsten Hoffmann
Department of Clinical Radiology, LMU-Klinikum-Grosshadern, University of Munich, Germany
Seth P. Lerner
Department of Urology, Baylor College of Medicine, Houston, TX
Florian Lohe
Department of Surgery, LMU-Klinikum-Grosshadern, University of Munich, Germany
Johanna Louhimo
Department of Clinical Chemistry, Helsinki University Central Hospital, Finland
Ihor Sawczuk
Department of Urology, Hackensack University Medical Center, Hackensack,NJ
Kazuhisa Taketa
Clinical Trial Center, Brain Attack Center, Oota Memorial Hospital, Fukuyama, Japan
Eleftherios P. Diamandis
Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, and Department of Laboratory Medicine and Pathobiology, University of Toronto, Ontario, Canada
This LMPG was developed by an independent committee of the NACB. Subsequent publication of these guidelines has been supported by the Academy.